To verify the concurrent or mutually exclusive nature of TERT amplification and TPM and the alleged association of TERT amplification with other oncogenic drivers in thyroid carcinogenesis, we investigated in the same cohort of tumors the presence of TPM, BRAF, HRAS, KRAS, NRAS, and PIK3CA mutations. The gene discussed is HRAS; the disease is thyroid gland disorder.